Four sufferers experienced respiratory muscles weakness
Four sufferers experienced respiratory muscles weakness. (range 7 to 15) to 0 (range 0 to 3; p = 0.011), as well as the MMS improved from 38.5 (range 24 to 60) to 100 (range 90 to 100; p = 0.012). These differences were all significant statistically. During RTX treatment and following follow-up, 1 individual reported minimal post-infusion malaise. Bottom line Low-dose RTX is effective and safe for treating anti-MuSK antibody positive MG sufferers. A long-term response is normally noticed after treatment. Bigger prospective studies must provide further proof. strong course=”kwd-title” Keywords: myasthenia gravis, rituximab, low-dose, muscle-specific kinase Launch Myasthenia gravis (MG) can be an obtained autoimmune disease from the postsynaptic neuromuscular junction seen as a fluctuating muscles weakness and exhaustion that may involve the skeletal muscle tissues.1 The pathogenic antibodies which have been discovered so far include anti-acetylcholine receptor antibody (AChR), muscle-specific receptor tyrosine kinase antibody (MuSK), and low-density lipoprotein…